PACIRA PHARMACEUTICALS INC's ticker is PCRX and the CUSIP is 695127100. A total of 261 filers reported holding PACIRA PHARMACEUTICALS INC in Q1 2023. The put-call ratio across all filers is 0.66 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $15,452,351 | -22.9% | 503,662 | +0.7% | 0.00% | -25.0% |
| Q2 2023 | $20,048,503 | -3.8% | 500,337 | -2.0% | 0.00% | 0.0% |
| Q1 2023 | $20,829,955 | +6.7% | 510,413 | +0.9% | 0.00% | 0.0% |
| Q4 2022 | $19,527,587 | -25.4% | 505,765 | +2.8% | 0.00% | -33.3% |
| Q3 2022 | $26,181,000 | -8.5% | 492,204 | +0.3% | 0.01% | 0.0% |
| Q2 2022 | $28,612,000 | -24.8% | 490,791 | -1.5% | 0.01% | -14.3% |
| Q1 2022 | $38,029,000 | +23.9% | 498,295 | -2.3% | 0.01% | +40.0% |
| Q4 2021 | $30,683,000 | +4.9% | 509,942 | -2.4% | 0.01% | 0.0% |
| Q3 2021 | $29,252,000 | -8.6% | 522,346 | -1.0% | 0.01% | -16.7% |
| Q2 2021 | $32,011,000 | -13.9% | 527,545 | -0.6% | 0.01% | -14.3% |
| Q1 2021 | $37,198,000 | +11.6% | 530,709 | -4.7% | 0.01% | +16.7% |
| Q4 2020 | $33,328,000 | -2.5% | 556,959 | -2.1% | 0.01% | -14.3% |
| Q3 2020 | $34,198,000 | +9.8% | 568,832 | -4.1% | 0.01% | 0.0% |
| Q2 2020 | $31,138,000 | +66.9% | 593,431 | +6.6% | 0.01% | +40.0% |
| Q1 2020 | $18,658,000 | -24.9% | 556,457 | +1.5% | 0.01% | -16.7% |
| Q4 2019 | $24,833,000 | +13.9% | 548,183 | -4.3% | 0.01% | +20.0% |
| Q3 2019 | $21,800,000 | -4.3% | 572,658 | +9.4% | 0.01% | 0.0% |
| Q2 2019 | $22,770,000 | +14.5% | 523,603 | +0.2% | 0.01% | 0.0% |
| Q1 2019 | $19,883,000 | -11.1% | 522,403 | +0.5% | 0.01% | -16.7% |
| Q4 2018 | $22,367,000 | -12.8% | 519,937 | -0.4% | 0.01% | 0.0% |
| Q3 2018 | $25,657,000 | +56.3% | 522,015 | +1.9% | 0.01% | +50.0% |
| Q2 2018 | $16,412,000 | +7.3% | 512,082 | +4.3% | 0.00% | 0.0% |
| Q1 2018 | $15,302,000 | -31.6% | 491,205 | +0.3% | 0.00% | -33.3% |
| Q4 2017 | $22,357,000 | +19.4% | 489,753 | -1.8% | 0.01% | +20.0% |
| Q3 2017 | $18,724,000 | -22.4% | 498,638 | -1.4% | 0.01% | -28.6% |
| Q2 2017 | $24,114,000 | +14.2% | 505,529 | +9.1% | 0.01% | +16.7% |
| Q1 2017 | $21,124,000 | +42.4% | 463,240 | +0.9% | 0.01% | +20.0% |
| Q4 2016 | $14,835,000 | -8.9% | 459,304 | -3.4% | 0.01% | 0.0% |
| Q3 2016 | $16,277,000 | +0.7% | 475,649 | -0.7% | 0.01% | 0.0% |
| Q2 2016 | $16,161,000 | -36.6% | 479,105 | -2.9% | 0.01% | -37.5% |
| Q1 2016 | $25,492,000 | -38.9% | 493,489 | -9.1% | 0.01% | -42.9% |
| Q4 2015 | $41,689,000 | +101.0% | 542,902 | +7.6% | 0.01% | +100.0% |
| Q3 2015 | $20,743,000 | -31.5% | 504,687 | +17.8% | 0.01% | -22.2% |
| Q2 2015 | $30,296,000 | -27.2% | 428,385 | -8.6% | 0.01% | -30.8% |
| Q1 2015 | $41,623,000 | +0.1% | 468,453 | -0.1% | 0.01% | 0.0% |
| Q4 2014 | $41,580,000 | -9.7% | 468,980 | -1.3% | 0.01% | -7.1% |
| Q3 2014 | $46,064,000 | +30.2% | 475,281 | +23.4% | 0.01% | +27.3% |
| Q2 2014 | $35,372,000 | +28.1% | 385,075 | -2.4% | 0.01% | +22.2% |
| Q1 2014 | $27,610,000 | +17.2% | 394,489 | -3.7% | 0.01% | +12.5% |
| Q4 2013 | $23,553,000 | +22.5% | 409,683 | +2.5% | 0.01% | +14.3% |
| Q3 2013 | $19,223,000 | +115.4% | 399,868 | +29.9% | 0.01% | +133.3% |
| Q2 2013 | $8,925,000 | – | 307,740 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Gagnon Advisors, LLC | 251,140 | $19,167,000 | 8.83% |
| GAGNON SECURITIES LLC | 610,933 | $46,626,000 | 7.60% |
| Tamarack Advisers, LP | 205,000 | $15,646,000 | 7.40% |
| Spyglass Capital Management LLC | 1,871,040 | $142,798,000 | 4.88% |
| Lisanti Capital Growth, LLC | 302,413 | $23,080,000 | 2.59% |
| Rock Springs Capital Management LP | 1,000,000 | $76,320,000 | 1.92% |
| MESIROW FINANCIAL INVESTMENT MANAGEMENT - Fixed Income | 208,197 | $15,890,000 | 1.76% |
| JABODON PT CO | 49,052 | $3,744,000 | 1.70% |
| Zweig-DiMenna Associates LLC | 166,675 | $12,721,000 | 1.70% |
| NEUMEIER POMA INVESTMENT COUNSEL LLC | 317,425 | $24,226,000 | 1.63% |